Whiting USA Trust II EV/EBIT
Cos'è EV/EBIT di Whiting USA Trust II?
EV/EBIT di Whiting USA Trust II è 0.32
Qual è la definizione di EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT di aziende nel Energy settore su OTC rispetto a Whiting USA Trust II
Cosa fa Whiting USA Trust II?
Whiting USA Trust II holds a term net profits interest in the oil and gas producing properties located in the Permian Basin, Rocky Mountains, Gulf Coast, and Mid-Continent regions of the United States. Its oil and gas properties include interests in approximately 364.1 net producing oil and natural gas wells located in 42 predominately mature fields with established production profiles in 8 states. The company was founded in 2011 and is based in Houston, Texas. Whiting USA Trust II is a subsidiary of Whiting Petroleum Corporation.
Aziende con ev/ebit simili a Whiting USA Trust II
- Oncternal Therapeutics ha EV/EBIT di 0.28
- Sulliden Mining Capital ha EV/EBIT di 0.29
- J4 Ventures ha EV/EBIT di 0.29
- Sulliden Mining Capital ha EV/EBIT di 0.30
- Bio-Path Inc ha EV/EBIT di 0.31
- Freeline Therapeutics plc ha EV/EBIT di 0.31
- Whiting USA Trust II ha EV/EBIT di 0.32
- Valencia Capital ha EV/EBIT di 0.33
- BlueCity ha EV/EBIT di 0.33
- Aclaris Therapeutics Inc ha EV/EBIT di 0.35
- Zafgen ha EV/EBIT di 0.35
- Xenetic Biosciences Inc ha EV/EBIT di 0.35
- Ocwen ha EV/EBIT di 0.35